Revenue and net profit grew year-over-year for both standalone and consolidated results in Q1 FY25, with improved margins and continued focus on the core pharmaceutical segment. Share-based payments and ESOP allotments were notable, and prior impairments reflect ongoing subsidiary risks.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.